Ocera raises $28M for PhIIb liver disease study

Ocera Therapeutics raised $28 million from a group of venture investors backing the biotech's work on orphan liver diseases. The San Diego-based biotech's lead therapy is OCR-002, ornithine phenylacetate, for the treatment of hepatic encephalopathy, which is slated to start a Phase IIb study later this year. Vivo Capital and Venrock spearheaded the round with additional participation from institutional investors Deerfield, Great Point Partners LLC, funds managed by QVT Financial LP, RA Capital Management, InterWest Partners and Three Arch Opportunity Fund. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.